AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29454333
Drug: Ultrasound-guided paravertebral
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided paravertebral block (PVB) with 0.5% bupivacaine, 15 mL
Trial: 29454333
Drug: Intravenous tramadol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tramadol, loading dose of 1 mg/kg
Trial: 26440201
Drug: Ti implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ti implants (4.1 mm diameter)
Trial: 26440201
Drug: Ti‐Zr implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ti‐Zr implants (3.3 mm diameter)
Trial: 26440201
Drug: Both Ti
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both Ti and Ti‐Zr implants
Trial: 24163236
Drug: Monthly telephone
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly telephone counselling (control)
Trial: 18179556
Drug: IL-6 at
RxNorm normalized name: IL-6
DrugBank: Human interleukin-6 (DB15060)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-6 at cut-off of 125 pg/ml
Trial: 12702979
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with rabeprazole, clarithromycin, and tinidazole plus lactoferrin for 7 days (group A)
Trial: 12702979
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with rabeprazole, clarithromycin, and tinidazole for 7 days (group B)
Trial: 12702979
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with rabeprazole, clarithromycin, and tinidazole for 10 days (group C)
Trial: 9411221
Drug: Antiarrhythmic-drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiarrhythmic-drug therapy (primarily amiodarone)
Trial: 8377779
Drug: 5,6-benzo-[alpha]-pyrone (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5,6-benzo-[alpha]-pyrone (400 mg for six months)
Trial: 2439814
Drug: bopindolol 2
RxNorm normalized name: bopindolol
DrugBank: Bopindolol (DB08807)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bopindolol 2 mg
Trial: 24880197
Drug: Cognitive functioning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive functioning and physical capacity assessed after 13 weeks of CRC supplementation (2.5 g per day of chicken meat extract containing 40% CRC components).
Trial: 22644963
Drug: Besifloxacin ophthalmic
RxNorm normalized name: besifloxacin ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Besifloxacin ophthalmic suspension 0.6% dosed twice daily
Trial: 20427668
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of prednisolone (synthetic mixed glucocorticoid/mineralocorticoid agonist)
Trial: 20427668
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of prednisolone
Trial: 20427668
Drug: Glucocorticoid receptor
RxNorm normalized name: Glucocorticoid receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucocorticoid receptor antagonist pretreatment
Trial: 12598380
Drug: Heptavalent pneumococcal
RxNorm normalized name: botulinum neurotoxin B immune FAB2
DrugBank: Equine Botulinum Neurotoxin B Immune FAB2 (DB13903)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heptavalent pneumococcal conjugate vaccine (7VPnCV)
Trial: 10696418
Drug: Artesunate plus
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Artesunate plus sulfadoxine-pyrimethamine (4 mg/kg for 3 days and 25 mg/kg sulfadoxine)
Trial: 8738856
Drug: Intact and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intact and dispersed josamycin Solutab tablet (1,000 mg)
Trial: 8738856
Drug: Josacine reference
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Josacine reference sachet (1,000 mg)
Trial: 19839170
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: 50 J/cm2/100 J/cm3 (laser/RF), two passes, three treatment sessions 30 days apart
Trial: 19839170
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: 30 J/cm2/50 J/cm3, three passes, five treatment sessions 15 days apart
Trial: 17590966
Drug: Structured music
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured music therapy groups
Trial: 6380179
Drug: 0.4 g
RxNorm normalized name: psyllium 0.4 GM Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 g of doxycycline preoperatively
Trial: 6380179
Drug: 0.2 g
RxNorm normalized name: methionine 0.2 gram ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 g of doxycycline preoperatively and 0.1 g of doxycycline on the first, second and third postoperative day
Trial: 28081952
Drug: Alteplase (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alteplase (1 mg, up to 12 doses, 8 h apart via extraventricular drain)
Trial: 28081952
Drug: Saline (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (0.9% saline, up to 12 doses, 8 h apart via extraventricular drain)
Trial: 26585569
Drug: Weekly GMA
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly GMA (one session per week)
Trial: 12639367
Drug: Fluoxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20 mg/day) plus tibolone (2.5 mg/day)
Trial: 1400054
Drug: Fluid Replacement
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid Replacement (FR) - carbohydrate-electrolyte fluid replacement solution sufficient to replace 80 ± 2% of sweat loss
Trial: 1400054
Drug: Blood Volume
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood Volume Expander (BVX) - 5.3 ml/kg of 6% dextran in saline
Trial: 2862419
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg vitamin K administered at birth
Trial: 2862419
Drug: Untreated group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Untreated group (no vitamin K administration)
Trial: 2862419
Drug: Vitamin K
RxNorm normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K administered to newborns with normotest levels < 30%
Trial: 20389176
Drug: 4-liter PEG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-liter PEG solution plus magnesium hydroxide
Trial: 20389176
Drug: 4-liter PEG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-liter PEG solution
Trial: 19277245
Drug: Omega-3 dietary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 dietary supplementation (two 1000-mg capsules 3 times a day)
Trial: 14624169
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg vitamin C, 800 mg vitamin E, 10 mg folic acid
Trial: 10760722
Drug: IAN +
RxNorm normalized name: Gentian + sodium bicarbonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IAN + IO injection with 1.8 mL of 1.5% etidocaine hydrochloride containing 1:200,000 epinephrine
Trial: 10760722
Drug: IAN +
RxNorm normalized name: Gentian + sodium bicarbonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IAN + mock IO injection
Trial: 10760722
Drug: IO injection
RxNorm normalized name: Io-Shield
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IO injection of etidocaine hydrochloride
Trial: 6469079
Drug: Lactose containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose containing diet (LC diet) - 150 g/d, high protein (112 g/d)
Trial: 6469079
Drug: Lactose free
RxNorm normalized name: Similac Lactose Free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose free diet (LF diet) - normal protein (67 g/d)
Trial: 30758744
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg ASA/200 mg paracetamol/50 mg caffeine (test)
Trial: 30758744
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg ASA/200 mg paracetamol (reference)
Trial: 25427964
Drug: Implants with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implants with a screwed tapered internal connection placed subcrestally (Group 1)
Trial: 25427964
Drug: Implants with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implants with a screwed tapered internal connection placed crestally (Group 2)
Trial: 25427964
Drug: Implants with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implants with an internal conical seal connection placed subcrestally (Group 3)
Trial: 25427964
Drug: Implants with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implants with an internal conical seal connection placed crestally (Group 4)
Trial: 15957832
Drug: Qinggan Jiangtang
RxNorm normalized name: Jianghuang
DrugBank: Turmeric (DB14276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qinggan Jiangtang tablet (QJT) 3 tabs, twice a day for 1 month
Trial: 15957832
Drug: Glucophage 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucophage 3 tabs, twice a day for 1 month
Trial: 10431273
Drug: iodixanol 320
RxNorm normalized name: IODIXANOL 320mgI/ml INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iodixanol 320 mgl/ml
Trial: 10431273
Drug: ioxaglate 320
RxNorm normalized name: ioxaglate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ioxaglate 320 mgl/ml
Trial: 7589030
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA, 1.0 g)
Trial: 7589030
Drug: Ibuprofen (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (0.8 g)
Trial: 7589030
Drug: Paracetamol (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (1.0 g)
Trial: 2209678
Drug: Cyclosporine A
RxNorm normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine A (CYA) 5 mg/kg/day
Trial: 28181639
Drug: Withdrawal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal of fall‐risk‐increasing‐drugs (FRIDs)
Trial: 25319761
Drug: ethinyl estradiol
RxNorm normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ethinyl estradiol (EE) 30 mcg/desogestrel 150 mcg plus spironolactone 25 mg/day (group A)
Trial: 25319761
Drug: ethinyl estradiol
RxNorm normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ethinyl estradiol (EE) 35 mcg/cyproterone acetate 2 mg (group B)
Trial: 23820059
Drug: Dutasteride 0.5
RxNorm normalized name: dutasteride 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dutasteride 0.5 mg per day
Trial: 19586937
Drug: Rituximab added
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab added to dose-dense and high-dose chemotherapy (R-MegaCEOP14, R-MAD, BEAM) with autologous stem cell transplantation
Trial: 19586937
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy without rituximab (MACOP-B, MAD, BEAM)
Trial: 17721968
Drug: Behaviorally intensive,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behaviorally intensive, contingency management treatment
Trial: 17721968
Drug: Less-intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Less-intensive treatment
Trial: 14756849
Drug: Zolmitriptan (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolmitriptan (2.5 mg or 5 mg based on migraine severity)
Trial: 11790416
Drug: Breakfast of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breakfast of 10 or 50 g of carbohydrate (corn flakes)
Trial: 11790416
Drug: Snack of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Snack of 25 g of carbohydrate (corn flakes) after 1 1/2 h
Trial: 7978128
Drug: Three vital
RxNorm normalized name: Vital-Chlor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three vital capacity breaths of room air during intravenous propofol administration (2.5 mg.kg‐1)
Trial: 2688586
Drug: Intravenous nicardipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nicardipine hydrochloride
Trial: 2688586
Drug: Subsequent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subsequent treatment with nicardipine after placebo failure
Trial: 1081271
Drug: Calcium (2
RxNorm normalized name: calcium (2ξ)-D-gluco-heptonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (2 g per day)
Trial: 31287199
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (mechanical diagnosis therapy and transforaminal epidural steroid injections)
Trial: 31648781
Drug: Experimental antiplatelet
RxNorm normalized name: simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental antiplatelet treatment strategy
Trial: 31648781
Drug: Reference antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference antiplatelet treatment strategy
Trial: 22712537
Drug: Ranibizumab (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab (0.5 mg in 0.05 mL) administered intravitreally at three time points: 9 days prior to surgery, 1 month post-surgery, and 2 months post-surgery.
Trial: 19263591
Drug: Calcium plus
RxNorm normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium plus vitamin D supplementation (600 mg elemental calcium and 5 microg vitamin D, consumed twice a day)
Trial: 7700070
Drug: cilazapril 2.5‐5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cilazapril 2.5‐5 mg daily for 6 months
Trial: 3662594
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of human growth hormone (hGH)
Trial: 3662594
Drug: Pulsatile treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsatile treatment with human growth hormone (hGH)
Trial: 3662594
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment with human growth hormone (hGH)
Trial: 29691197
Drug: Motivational Intervention‐Medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational Intervention‐Medication Therapy Management (MI‐MTM)
Trial: 15870721
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (4 mg) administered in the community setting
Trial: 15870721
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (4 mg) administered in the hospital setting
Trial: 11100343
Drug: Somatostatin 250
RxNorm normalized name: Somatostatine
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin 250 mcg i.v. bolus followed by continuous i.v. infusion at a rate of 6 mg/d for 72 h
Trial: 11100343
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 mg/d by continuous i.v. infusion for 72 h
Trial: 9581001
Drug: Twelve-Step Facilitation
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Twelve-Step Facilitation Therapy (TSF)
Trial: 3529884
Drug: Aspirin +
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin + Diclofenac
Trial: 29573375
Drug: 4% articaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% articaine with buccal intrapapillary infiltration
Trial: 29573375
Drug: 2% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine with inferior dental nerve block and long buccal infiltration
Trial: 24404799
Drug: Daily preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily preventive asthma medication prescribed (current prescription)
Trial: 16548349
Drug: Wuling pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wuling pill (WLP) plus conventional therapy
Trial: 9006746
Drug: Placebo (oral,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (oral, twice daily on days 2-6)
Trial: 9006746
Drug: Ondansetron (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (8 mg oral, twice daily on days 2/3 followed by placebo on days 4-6)
Trial: 9006746
Drug: Ondansetron (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (8 mg oral, twice daily on days 2-6)
Trial: 9006746
Drug: Ondansetron (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (8 mg oral, twice daily) plus Dexamethasone (4 mg oral, twice daily on days 2-6)
Trial: 31210529
Drug: Tofogliflozin 20
RxNorm normalized name: sotagliflozin
DrugBank: Sotagliflozin (DB12713)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Tofogliflozin 20 mg/day
Trial: 24725442
Drug: Apixaban 2.5
RxNorm normalized name: apixaban 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban 2.5 mg
Trial: 24725442
Drug: Apixaban 5
RxNorm normalized name: apixaban 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban 5 mg
Trial: 18847418
Drug: Calcium compounds
RxNorm normalized name: Calcium compounds
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium compounds
Trial: 10871712
Drug: MDMA (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDMA (1.5 mg/kg p.o.)
Trial: 10871712
Drug: Haloperidol (1.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (1.4 mg i.v.)
Trial: 9347436
Drug: Oxycodone 0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone 0.04 mg/kg
Trial: 9347436
Drug: Tramadol 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 0.6 mg/kg
Trial: 8471816
Drug: Combined preoperative
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined preoperative treatment (group 1)
Trial: 28029926
Drug: n‐3 LCPUFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n‐3 LCPUFA (fish oil) 2.4 g per day
Trial: 24970858
Drug: DHA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA supplementation (2,000 mg)
Trial: 24970858
Drug: Control (identical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (identical soy/corn oil capsules)
Trial: 22861493
Drug: Medication and
RxNorm normalized name: CVS Health Medication and Topical Refill Pouch KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication and clinical records
Trial: 18318945
Drug: Amoxicillin (oral,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (oral, twice daily for 5 days)
Trial: 18318945
Drug: Ceftriaxone (intramuscular,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (intramuscular, once daily for 2 days)
Trial: 16704037
Drug: TB treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TB treatment for 4 months under direct observation after 2 months of initial treatment
Trial: 16704037
Drug: Extent of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extent of disease and treatment failure/relapse
Trial: 10965418
Drug: benidipine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: benidipine (4 mg/day)
Trial: 1335646
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of immune globulin (Ig) and hepatitis A vaccine
Trial: 1335646
Drug: Hepatitis A
RxNorm normalized name: HEPATITIS A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis A vaccine alone
Trial: 1335646
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Ig and vaccine
Trial: 28474341
Drug: Dexamethasone 8
RxNorm normalized name: dexamethasone 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 8 mg, n = 40
Trial: 18574679
Drug: Intensive intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive intervention (physician advice, in-person counseling with nicotine replacement therapy, 5 telephone calls)
Trial: 17043424
Drug: Prophylactic antibiotics
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic antibiotics (intravenous cefotaxime 2 g q 8 hr for 7 days)
Trial: 17043424
Drug: On-demand antibiotics
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-demand antibiotics (same antibiotics only when infection became evident)
Trial: 7494588
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy in patients with preinfarction angina